Skip to content

Netherlands logo

Main menu
    • About us
    • Our focus
    • Our products
    • Business development
    • Our leaders
    • Our culture
    • Policies & positions
    • Environmental, social & governance
    • Diversity, equity, inclusion & belonging
    • News
    • Media
  • Join our team

Contact Us

Back
Change Language
  • Nederlands
Main menu

Organon site directory

  • Organon

    • Brazil
    • Canada  English  ·  French
    • Latin America
    • Mexico
    • USA
  • Organon

    • Austria
    • Belgium  Dutch  ·  English  ·  French
    • Bulgaria
    • Czech Republic
    • Denmark
    • Estonia
    • Finland
    • France
    • Germany
    • Hungary
    • Ireland
    • Italy
    • Latvia
    • Lithuania
    • Luxembourg  English  ·  French
    • Netherlands  Dutch  ·  English
    • Norway
    • Poland
    • Portugal
    • Romania
    • Russia
    • Serbia
    • Slovakia
    • Slovenia
    • Spain
    • Sweden
    • Switzerland  French  ·  German  ·  English
    • Ukraine  Ukrainian  · 
    • United Kingdom
  • Organon

    • Australia
    • Hong Kong, China
    • Indonesia
    • Japan
    • Malaysia
    • New Zealand
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Organon

    • Egypt
    • Israel
    • Jordan
    • KSA
    • Kuwait
    • Lebanon
    • Northwest Africa  French  ·  Arabic  ·  Turkey
    • Oman
    • South Africa
    • Turkey
    • UAE
View all locations and contact information

What can we help you find?

Search for:

Organon and Titus Health Care join forces for optimal freedom of choice in contraception

Save Print

January 27, 2022 4:01 pm EDT

AMSTERDAM – Healthcare company Organon will collaborate in the Netherlands with Titus Health Care, which supports gynecologists, obstetricians, abortion doctors and general practitioners in providing optimal contraceptive care. Both companies have the ambition to make a difference in women’s health. One of the spearheads is to offer them optimal freedom of choice in the field of contraceptive methods.

At its launch in June 2021, Organon launched a commitment: to listen to women worldwide, to understand ‘her’ health needs and help identify solutions that are urgently needed. “Because there is a need to address diseases and conditions that only or disproportionately impact women”, says Petra Willems, Managing Director of Organon Benelux. “Our impact will go beyond medicine, contraception and fertility treatments. Because we know that we can do so much more for women and their health. That is why we are proud that we have been able to realize a strategic partnership in the Benelux so quickly.”

A lot of experience
Establishing close collaboration with external partners is a key tenet in the Organon strategy, whether it is to develop new therapies or to give more women access to existing products. The partnership with the Dutch company Titus Health Care is an excellent example of this.
Freek Hendriksen, who is responsible for Alliance & Business Development within the management team of Organon Benelux, says: “The Titus Health Care team is very experienced in training healthcare professionals and has a large network and a strong reputation in healthcare. Its entrepreneurial culture and mindset are also an excellent fit with Organon’s.”

From left to right:
Petra Willems and Freek Hendriksen of Organon Benelux together with Judith Wiegant and Joep de Mönnink (Titus Health Care).


Join forces
Together, the companies will work on improving awareness of and access to long-acting contraceptive methods. “Every woman is unique and that requires tailormade contraceptive advice. That is why Titus Health Care and Organon are joining forces. We share the ambition to contribute to the education of healthcare providers so that they can give women appropriate advice about contraception,” says Judith Wiegant, Managing Director of Titus Health Care.
“We are joining forces with a broad portfolio of hormonal and non-hormonal contraception”, adds the company’s founder and co-director Joep de Mönnink. “To offer women optimal freedom of choice.”


VVPM job number Organon Benelux partnership with Titus Health Care: NL-NON-110020

What can we help you find?

Search for:
Netherlands logo
  • Forward-Looking Statement
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
© 2025 Organon group of companies. All rights reserved. ORGANON and the ORGANON Logo are trademarks of the Organon group of companies.

You are leaving Organon.com

Cancel Continue Opens a new window

Forward-looking statement of Organon

This news release of Organon (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov Opens a new window ).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

Decline Accept